会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明申请
    • DIGITAL VIDEO POSTER
    • 数字视频海报
    • WO2011041889A1
    • 2011-04-14
    • PCT/CA2010/001574
    • 2010-10-05
    • PLASTIC KNOWLEDGE INC.ANDREWS, MarkFONG, BellFONG, William
    • ANDREWS, MarkFONG, BellFONG, William
    • H05B33/12G09F9/30G09G3/20H05B33/26
    • H05B33/145
    • A substantially plastic digital video poster having a plurality of superposed layers of different compositions and characteristics that combine to form a pixilated addressable flexible display with an embedded functionality. The plastic digital video poster comprises an emissive composite. The emissive composite comprises superposed first and second panel assemblies. The first panel assembly comprises a first plurality of conductors. The second panel assembly comprise a second optically transmissive plurality of conductors and an emissive layer interposed between the first and second plurality of conductors. The emissive composite comprises a first substrate with a first plurality of conductors coupled thereto. A dielectric layer is coupled to the first plurality of conductors and to an emissive layer. A second optically transmissive plurality of conductors also coupled to a second substrate and an emissive layer is interposed between the first and second plurality of conductors.
    • 一种基本上塑料的数字视频海报,其具有组合以形成具有嵌入功能的像素化可寻址的柔性显示器的不同组合和特征的多个叠加层。 塑料数字视频海报包括发射复合材料。 发光复合材料包括叠置的第一和第二面板组件。 第一面板组件包括第一组多个导体。 第二面板组件包括第二光学透射多个导体和介于第一和第二多个导体之间的发射层。 发射复合材料包括具有与其耦合的第一多个导体的第一基板。 介电层耦合到第一多个导体和发射层。 还耦合到第二衬底和发射层的第二透光多个导体插入在第一和第二多个导体之间。
    • 4. 发明申请
    • N-PYRROLIDIN-3-YL-AMIDE DERIVATIVES AS SEROTONIN AND NORADRENALIN RE-UPTAKE INHIBITORS
    • N-吡咯烷-3-基酰胺衍生物作为丝氨酸和诺达霉素重新吸收抑制剂
    • WO2006064351A3
    • 2006-10-12
    • PCT/IB2005003791
    • 2005-12-08
    • PFIZER LTDANDREWS MARK DAVIDBROWN ALAN DANIELFISH PAUL VINCENTFRAY MICHAEL JONATHANLANSDELL MARK IANRYCKMANS THOMASSTOBIE ALANVAKENHUT FLORIANGRAY DAVID LAWRENCE FIRMAN
    • ANDREWS MARK DAVIDBROWN ALAN DANIELFISH PAUL VINCENTFRAY MICHAEL JONATHANLANSDELL MARK IANRYCKMANS THOMASSTOBIE ALANVAKENHUT FLORIANGRAY DAVID LAWRENCE FIRMAN
    • C07D207/34A61K31/40A61P13/00A61P25/24A61P29/00C07D211/58C07D401/12
    • C07D207/14C07D211/58C07D401/12
    • A compound of Formula (I) and pharmaceutically and/or veterinarily acceptable derivatives thereof, wherein: R 1 is H, C 1-6 alkyl, -C(A)Y, C 3-8 cycloalkyl, aryl, het, aryl-C 1-4 alkyl or het-C l-4 alkyl, wherein the cycloalkyl, aryl or het groups are optionally substituted; A is S or O; Y is H, C 1-6 alkyl, aryl, het, aryl-C 1-4 alkyl or het­-C 1-4 alkyl; aryl is independently selected from phenyl, naphthyl, anthracyl or phenanthryl; het is independently selected from an aromatic or non-aromatic 4-, 5- or 6- membered heterocycle which contains at least one N, O or S heteroatom, optionally fused to a 5- or 6- membered carbocyclic group or a second 4-, 5- or 6-membered heterocycle which contains at least one N, O or S heteroatom; R 2 is aryl 1 or het 1 , each optionally substituted; aryl 1 is independently selected from phenyl, naphthyl, anthracyl, phenanthryl, or indanyl; het 1 is an aromatic 5 to 10 membered heterocyclic ring system which contains at least one N, O or S heteroatom, optionally containing an aryl group; R 3 is H, C 1-8 alkyl, C 3-8 cycloalkyl, C 3-8 cycloalkyl-C 1-6 alkyl, C 1-8 alkylSC 1-8 alkyl, het 3 , or het 3 -C 1-4 alkyl, wherein the alkyl, cycloalkyl and het 3 groups are each optionally substituted; het 3 is a non-aromatic 4-, 5- or 6- membered heterocycle which contains at least one N, O or S heteroatom, optionally fused to a 5- or 6- membered carbocyclic group or a second 4-, 5- or 6-membered heterocycle which contains at least one N, O or S heteroatom; or R 3 is (CH 2 ) a
    • 式(I)化合物及其药学和/或兽医学上可接受的衍生物,其中:R 1是H,C 1-6烷基,-C(A)Y C 3-8环烷基,芳基,苯基,芳基-C 1-4烷基或叔-C 1-4烷基,其中 环烷基,芳基或苯基基团任选被取代; A是S或O; Y是H,C 1-6烷基,芳基,苯基,芳基-C 1-4烷基或叔丁基C 1-4烷基 ; 芳基独立地选自苯基,萘基,蒽基或菲基; 独立地选自芳族或非芳族的4-,5-或6-元杂环,其含有至少一个N,O或S杂原子,任选地与5-或6-元碳环基团或第二4- 含有至少一个N,O或S杂原子的5-或6-元杂环; R 2是每个任选被取代的芳基1或1或1; 芳基1独立地选自苯基,萘基,蒽基,菲基或茚满基; 包含至少一个任选含有芳基的N,O或S杂原子的芳族5至10元杂环系统; R 3是H,C 1-8烷基,C 3-8环烷基,C 3-8环烷基 C 1-6烷基,C 1-8烷基,C 1-6烷基,H 3或H 3 其中烷基,环烷基和叔丁基各自任选被取代; 它是非芳族的4-,5-或6-元杂环,其含有至少一个N,O或S杂原子,任选地与5-或6-元碳环基团或 含有至少一个N,O或S杂原子的第二个4-,5-或6-元杂环; 或者R 3是(CH 2)2。
    • 5. 发明申请
    • NOVEL COMPOUNDS
    • 新型化合物
    • WO2006064351A2
    • 2006-06-22
    • PCT/IB2005/003791
    • 2005-12-08
    • PFIZER LIMITEDANDREWS, Mark, DavidBROWN, Alan, DanielFISH, Paul, VincentFRAY, Michael, JonathanLANSDELL, Mark, IanRYCKMANS, ThomasSTOBIE, AlanVAKENHUT, FlorianGRAY, David, Lawrence, Firman
    • ANDREWS, Mark, DavidBROWN, Alan, DanielFISH, Paul, VincentFRAY, Michael, JonathanLANSDELL, Mark, IanRYCKMANS, ThomasSTOBIE, AlanVAKENHUT, FlorianGRAY, David, Lawrence, Firman
    • C07D207/34C07D401/12C07D211/58A61K31/40A61P13/00A61P25/24A61P29/00
    • C07D207/14C07D211/58C07D401/12
    • A compound of Formula (I) and pharmaceutically and/or veterinarily acceptable derivatives thereof, wherein: R 1 is H, C 1-6 alkyl, -C(A)Y, C 3-8 cycloalkyl, aryl, het, aryl-C 1-4 alkyl or het-C l-4 alkyl, wherein the cycloalkyl, aryl or het groups are optionally substituted; A is S or O; Y is H, C 1-6 alkyl, aryl, het, aryl-C 1-4 alkyl or het­-C 1-4 alkyl; aryl is independently selected from phenyl, naphthyl, anthracyl or phenanthryl; het is independently selected from an aromatic or non-aromatic 4-, 5- or 6- membered heterocycle which contains at least one N, O or S heteroatom, optionally fused to a 5- or 6- membered carbocyclic group or a second 4-, 5- or 6-membered heterocycle which contains at least one N, O or S heteroatom; R 2 is aryl 1 or het 1 , each optionally substituted; aryl 1 is independently selected from phenyl, naphthyl, anthracyl, phenanthryl, or indanyl; het 1 is an aromatic 5 to 10 membered heterocyclic ring system which contains at least one N, O or S heteroatom, optionally containing an aryl group; R 3 is H, C 1-8 alkyl, C 3-8 cycloalkyl, C 3-8 cycloalkyl-C 1-6 alkyl, C 1-8 alkylSC 1-8 alkyl, het 3 , or het 3 -C 1-4 alkyl, wherein the alkyl, cycloalkyl and het 3 groups are each optionally substituted; het 3 is a non-aromatic 4-, 5- or 6- membered heterocycle which contains at least one N, O or S heteroatom, optionally fused to a 5- or 6- membered carbocyclic group or a second 4-, 5- or 6-membered heterocycle which contains at least one N, O or S heteroatom; or R 3 is (CH 2 ) a , K, wherein a' is 0, 1 or 2 and K is a group selected from: Formula (i) wherein: Z is O, S, NR 12 , (CH 2 ) V or a bond; a is 1, 2, 3 or 4; b is 1, 2 or 3; v is 1 or 2; R 10 and R 11 are each independently H or C 1-4 alkyl; R 12 is H, C 1-6 alkyl, C(O)C 1-6 alkyl, SO 2 -C 1-6 alkyl; and wherein one or more pairs of hydrogen atoms on adjacent carbon or nitrogen atoms may be replaced by a corresponding number of double bonds, provided the ring system is not aromatic; Formula (ii) a carbocyclic spiro group containing 6 to 12 carbon atoms; Formula(iii) wherein: c is 1, 2, 3 or 4; d is 1, 2 or 3; e is 1 or 2; and R 30 is H or C 1-4 alkyl; and wherein one or more pairs of hydrogen atoms on adjacent carbon atoms may be replaced by a corresponding number of double bonds, provided the ring system is not aromatic; Formula (iv) wherein: f is 0, 1, 2 or 3; L is SO, SO 2 or NR 40 ; and R 40 is H, C 1-6 alkyl, C(O)C 1-6 alkyl, SO 2 -C 1-6 alkyl; and wherein one or more pairs of hydrogen atoms on adjacent carbon atoms may be replaced by a corresponding number of double bonds, provided the ring system is not aromatic; Formula (v) wherein: g is 0, 1, 2 or 3; and R 50 is H, C 1-8 alkyl, C 1-8 alkoxy, OH, halo, CF 3 , OCHF 2 , OCF 3, SCF 3 , hydroxy-C 1-6 alkyl, C 1-4 alkoxy-C 1-6 alkyl and C 1-4 alkyl-S-C 1-4 alkyl; and Formula (vi) CH(cyclopropane) 2 ; X is a covalent bond, C 1-8 alkyl or C 3-8 cycloalkyl, wherein if X is C 3-8 cycloalkyl, then R 2 -X may form a fused aryl-cycloalkyl ring system; and n is 1 or 2, provided that when n is 1, m is 0 or 1 and when n is 2, m is 0, wherein if m is 0, then * represents a chiral centre.
    • 式(I)化合物及其药学和/或兽医学上可接受的衍生物,其中:R 1是H,C 1-6烷基,-C(A)Y C 3-8环烷基,芳基,苯基,芳基-C 1-4烷基或叔-C 1-4烷基,其中 环烷基,芳基或苯基基团任选被取代; A是S或O; Y是H,C 1-6烷基,芳基,苯基,芳基-C 1-4烷基或叔丁基C 1-4烷基 ; 芳基独立地选自苯基,萘基,蒽基或菲基; 独立地选自芳族或非芳族的4-,5-或6-元杂环,其含有至少一个N,O或S杂原子,任选地与5-或6-元碳环基团或第二4- 含有至少一个N,O或S杂原子的5-或6-元杂环; R 2是每个任选被取代的芳基1或1或1; 芳基1独立地选自苯基,萘基,蒽基,菲基或茚满基; 包含至少一个任选含有芳基的N,O或S杂原子的芳族5至10元杂环系统; R 3是H,C 1-8烷基,C 3-8环烷基,C 3-8环烷基 C 1-6烷基,C 1-8烷基,C 1-6烷基,H 3或H 3 其中烷基,环烷基和叔丁基各自任选被取代; 它是非芳族的4-,5-或6-元杂环,其含有至少一个N,O或S杂原子,任选地与5-或6-元碳环基团或 含有至少一个N,O或S杂原子的第二个4-,5-或6-元杂环; 或R 3是(CH 2)2,...,